Introduction
To invade, breast cancer cells reduce their intercellular cohesion, lose polarity, enhance their motility and proteolytic activity, and acquire mesenchymal cell characteristics, undergoing a dramatic remodeling of the cytoskeleton in a process similar to the epithelial-mesenchymal transition (EMT) that takes place during embryogenesis (1, 2) . Invasive carcinomas may then spread through lymphatic or vascular channels and metastasize to regional lymph nodes and distant sites.
Functional loss of E-cadherin (CDH1) in an epithelial cell has been considered a hallmark of EMT. CDH1 expression may be repressed by transcription factors such as Snail (SNAI1), ZEB1 and Slug (2) (3) (4) . Snail belongs to a family of zinc-finger-containing transcriptional repressors implicated in the regulation of the EMT phenomenon (5) and, accordingly, Snail transfection into epithelial cells leads to a more fibroblastic phenotype (3) .
E-cadherin expression may also be controlled by its internalization and subsequent degradation by the proteosome system, mainly mediated by Hakai, an E3 ubiquitinligase that interacts with E-cadherin, inducing ubiquitination of the complex. Expression of Hakai in epithelial cells disrupts cell-cell contacts and enhances endocytosis of E-cadherin and cell motility (6) .
Although in invasive lobular carcinoma of the breast there is almost a universal loss of E-cadherin expression, in non-lobular invasive carcinomas, its absence is not so common, but may play a role in progression, development of distant metastases and recurrence (7) (8) (9) .
Our aim was to determine whether there are differences in E-cadherin, Snail and Hakai transcript expression (related to the EMT) between paired tumor and adjacent normal tissue from patients with invasive ductal breast carcinoma. Additionally, we also determined whether the tumoral expression of these genes could be associated with cell shedding and consequent regional and distant metastases.
Patients and Methods
Thirty patients were prospectively recruited at two reference cancer centers in São Paulo, Brazil: Hospital do Câncer A.C. Camargo and Instituto Brasileiro de Controle do Câncer, from December 2003 to November 2005. The study was approved by the Institutional Ethics Committee and written informed consent was signed by all participants. Fresh tumor and adjacent normal tissue samples were collected from these patients during tumor resection for epithelial cell recovery and gene expression analysis.
The median age of the patients was 53 years (Table  1) , 76.7% of the women were postmenopausal, 53.3% presented T1 lesions, and 50.0% presented lymph node involvement. Thirty-five percent of the patients presented pathological stage III disease and none of them had distant metastases, as evaluated by abdominal ultrasound, chest radiographs (posteroanterior and lateral) and a bone scan. Invasive ductal carcinoma was diagnosed in all patients, being histologic grade 3 in 27.6% of cases. Immunohistochemical expression of estrogen receptor, progesterone receptor and ERBB2 was detected in 86.7, 76.7 and 24.1% of the tumors, respectively. None of the patients had been previously treated for a breast carcinoma.
Another group of 30 patients with invasive ductal carcinoma diagnosed between 1994 and 1995 at Hospital do Câncer A.C. Camargo with a long-term follow-up (at least 5 years, median 93.3 months) had paraffin-embedded tumor samples available for immunohistochemistry reactions. Median age was 48.5 years (Table 2) and patients had at least 13 lymph nodes dissected during the surgical procedure. Twenty-one of these patients were assigned to a good prognosis group since they did not present lymph node involvement at diagnosis and had not developed regional or distant metastases during the follow-up period. Nine patients were assigned to a poor prognosis group since they presented histopathological involvement of axillary nodes upon diagnosis. In addition, 1 of them presented a distant metastasis at diagnosis (clinical stage IV disease) and the other 8 developed distant metastases. Breast cancer death followed after 18.1-80 months. Seventy-one and 22% of the patients were premenopausal in the good and poor prognosis group, respectively (P = 0.02, Fisher exact test). Estrogen receptor immunoexpression was positive in 12/19 and 2/7 patients of the good and poor prognosis groups, respectively (P = 0.190, Fisher exact test).
Sample harvesting and processing
Fresh tumor samples and corresponding peritumoral tissue situated at least 1 cm from the visual border of the tumor were collected during surgery. Tumor and peritumoral samples were individually subjected to mechanical disaggregation using scalpel blades and to enzymatic disaggregation using 2 mg/mL type 1 collagenase and 2 mg/mL hyaluronidase (Sigma-Aldrich, UK) for 18 h at 37°C, with intermittent shaking. After filtering, the resulting cell suspension was submitted to epithelial cell positive selection with Dynabead (CELLection Epithelial Enrich, Dynal Biotech, USA).
Tumor cells released from the primary site into vascular channels may be detected in the mononuclear compartment of blood samples. To avoid contamination with cutaneous epithelial cells, the first 3 mL blood was discarded after venipuncture and 10 mL blood was collected with a second syringe. Mononuclear cells (MNCs) were recovered after a density gradient using Ficoll-Paque PLUS (Amersham Biosciences, GE HealthCare Bio-Sciences Corp., USA).
Immunomagnetic epithelial cell separation
Dynabeads, used for epithelial cell selection, are superparamagnetic polystyrene beads coated with anti-human Ber-EP4 antibody, directed against a 34-and 49-kD glycopeptide expressed by human epithelial cells (10) .
Each tumor (or peritumoral) cell suspension was mixed with 125 µL Dynabeads for 3 h at 4°C with gentle rotation. The rosetted cells were isolated by placing the tube in a Dynal magnetic particle concentrator (Dynal Biotech) for 6 min at 4°C. The same procedure was carried out to recover epithelial cells from blood mononuclear cells, which were incubated with 25 µL Dynabeads.
To evaluate the efficacy of cell enrichment using this procedure, MCF-7 breast cancer cells were co-cultivated with fibroblasts (F) for 48 h (1 F:10 MCF-7) and, after trypsinization, the cell suspension was incubated with Dynabeads as described. Cytospins revealed that all recovered cells were cytokeratin-positive (data not shown).
RNA extraction, reverse transcription and real-time RT-PCR
Total RNA was isolated using the Trizol reagent (Invitrogen Life Technologies, USA) according to the manufacturer protocol. One microgram RNA was incubated for 15 min at room temperature with DNase I (1 U/μg; Invitrogen). RNA quality was confirmed by absorbance measurement ratio 260/280, which was >1.7, and by observation of 18S/28S rRNA by agarose gel (1%) electrophoresis under denaturing conditions and visualization with ethidium bromide (ratio >1.0). The reverse transcription reaction was carried out using hexamer random primers (Amersham Biosciences), dNTPs and Superscript™ (Invitrogen Life Technologies).
PCR primer sets (Table 3) were designed based on full length gene sequences in separated exons, in the coding region closer to the 3' end of the gene using the software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). BLAST analysis of the primers was carried out to confirm uniqueness at www.ncbi.nlm.nih.gov/blast.
Amplification reactions were carried out using 2 µL cDNA diluted 1:10, platinum Taq polymerase (Invitrogen); Expression of five housekeeping genes (ACTB, TFRC, GUSB, PPIA, and RPLP0) was first tested in 15 breast cancer samples (11) and expression of ACTB and RPLP0 was the most stable among samples. ACTB was then chosen as a reference gene. Relative expression of genes of interest was normalized to that of HB4A cells (normal mammary epithelial lineage). Investigated transcripts showed high real-time PCR efficiency rates (around 1.0) and relative expression was calculated as 2 -ΔΔCT . Results were then transformed to their natural logarithm values.
Detection of circulating epithelial cells using nested RT-PCR
Epithelial cells recovered from peripheral blood MNCs after immunoselection with Dynabeads had their mRNA extracted and processed by nested PCR to evaluate the expression of cytokeratin 19 (KRT19), a protein expressed by epithelial cells. The first reaction took place in the presence of 1 µL cDNA, Taq recombinant DNA Polymerase (Invitrogen) and external primers (Table 3) . Amplification conditions consisted of 95°C for 2 min, followed by 35 cycles at 95°C for 15 s, 62°C for 1 min, and 72°C for 1 min. The second PCR was performed using 1 µL of the product of the first reaction and a second pair of internal primers (Table  3) , under the same conditions as described above, for 25 amplification cycles. The product was detected under UV light as a band of 461 bp on 2% agarose gel containing ethidium bromide.
To establish the ideal number of amplification cycles, a serial dilution of HB4A cells (2, 5 and 10 cells) with promyelocytic leukemia HL60 cells (1 x 10 6 ) was performed. The first round of PCR revealed no product. The second PCR, performed using a variable number of cycles, revealed a characteristic product after 25 cycles for all dilutions of HB4A cells in HL60 cells ( Figure 1A ).
Immunohistochemistry
Sections (3-µm thick) were cut from paraffin blocks containing invasive cancer, and immunohistochemistry reactions were carried out to detect E-cadherin (mouse monoclonal IgG1 anti-human antibody, clone NCH-38, DAKO M3612, dilution 1:100) (DAKO Corporation, USA) or SNAI1 [(E-18): sc-10432 goat polyclonal IgG anti-human SNAI1 internal region; Santa Cruz Biotechnology, Inc., USA, dilution 1:50] with antigen retrieval performed by pressure cooking in 10-mM citrate buffer at pH 6.0 for 4 min. Detection was done using the StreptAB Complex/ HRP duet (Dako k492, 1:200) or horseradish peroxidase anti-goat IgG conjugate (Vector Labs, USA) and DAB (Sigma D5637; Sigma-Aldrich Corp., USA).
E-cadherin staining was evaluated as negative, if absent or low (no immunostaining or immunopositivity ≤10% or low-intensity partial membrane staining in >10% of cells) or positive (low, moderate or intense complete membrane staining in >10% of cells). The entire tumor represented in the section was assessed. Appropriate positive and negative controls were run with each batch (lobular and ductal invasive carcinomas).
Snail expression was evaluated as negative (nil or ≤10% of cells) or positive (>10% of cells). Negative controls were obtained by the omission of the primary antibody. Immunostaining for Snail was mainly observed in the cytoplasm and only two patients presented nuclear staining.
Statistical analysis
The Kolmogorov-Smirnov test of normality was applied to verify the distribution pattern of expression values. A normal distribution was detected for expression values of matched tumor/peritumor samples and therefore parametric tests (paired t-test and Pearson correlation) were used. When normal distribution was not detected, non-parametric tests (Mann-Whitney for independent variables, and Spearman correlation) were used. The level of significance was set at ≤0.05 in all analyses. Association between variables was determined using the Fisher exact test. The SPSS statistical software version 11.0 (USA) was used. 
Results
A paired analysis of the expression of E-cadherin (CDH1), Snail (SNAI1) and Hakai transcripts between the selected epithelial malignant component of tumors and its adjacent normal tissue was performed. Our data indicate that the expression levels of these target genes are widely distributed (Figure 2) , irrespective of the tissue origin (tumor or normal).
CDH1 mRNA expression was evaluated in 22 paired samples and a positive correlation was detected between them (r = 0.697; P < 0.01; Pearson correlation); however, no differential expression between the primary tumor (0.12 ± 2.51) and corresponding peritumoral tissue (-0.34 ± 2.45) was observed ( Figure 2 ). SNAI1 mRNA expression was evaluated in 25 paired samples and neither differential expression (primary tumor = 3.59 ± 2.31 vs peritumoral tissue = 3.59 ± 2.31) nor correlation between pairs was detected. Hakai mRNA expression was determined in 22 paired samples and no correlation was observed. Although there was no significant differential expression of HAKAI between matched samples (primary tumor = 2.30 ± 2.47 vs peritumoral tissue = 1.28 ± 2.67), 12 tumor specimens showed a higher expression (samples 4, 5, 11, 12, 15, 16, 18, 21, 22, 24, 28, 29) compared to the corresponding peritumoral samples (Figure 2) .
A positive correlation was detected between tumoral expression of E-cadherin and Snail (N = 18, r = 0.564, P = 0.015, Spearman correlation) and Snail and Hakai (N = 19, r = 0.611, P = 0.005, Spearman correlation). A trend towards a positive correlation between E-cadherin and Hakai expression was also observed (N = 15, r = 0.454, P = 0.089, Spearman correlation).
mRNA expression of all three target genes was analyzed in 13 matched samples (tumor and peritumoral) and discriminant analysis was performed using these variables. However, only 65.4% of the originally grouped cases would be correctly classified (Figure 3 ), indicating that these parameters could not be used for this purpose.
We then evaluated whether there were differences in tumor gene expression between patients with involved nodes and patients with uninvolved nodes. However, we observed no differences in E-cadherin, Snail or Hakai mRNA tumor expression according to the presence of regional metastases ( Figure 4A ).
We also determined whether E-cadherin, Snail and Hakai mRNA tumor expression was associated with the presence of circulating malignant cells, as determined by KRT19 expression in blood MNCs ( Figure 1B) . Circulating tumor cells were detected in blood samples from three of 13 patients. Boxplots ( Figure 4B ) suggest that there was a trend towards a lower E-cadherin mRNA expression (but not Snail or Hakai) in tumor samples from these patients with circulating tumor cells. In addition, we determined whether E-cadherin and Snail immunoexpression could be associated with breast cancer distant metastases and death in another group of patients with a minimum follow-up of five years ( Figure  5) . Negative E-cadherin expression was observed in 6 samples, 4 of them belonging to the poor prognosis group (Table 4) and inversely, positive E-cadherin expression was observed in 24 tumor specimens, 19 of them from the good prognosis group. These data indicate an association between E-cadherin protein negativity and poor prognosis and, conversely, between positivity and good prognosis (Table 4) . Positive Snail expression was observed in 16 samples but no association with the prognosis group was detected (Table 4 ).
Discussion
Our assumption was that invasive ductal carcinomas might present changes in E-cadherin, Snail or Hakai mRNA expression as compared to their paired normal adjacent tissue; however, no differential expression was observed. Our data indicate that invasive carcinomas and their normal adjacent tissue share the same characteristics concerning the mRNA expression of these genes, i.e., if expression is low in the tumor, it is also low in the normal adjacent tissue and vice-versa. One limitation of our study was the small sample size, its strength was that the epithelial compo- Table 4 . E-cadherin and Snail immunoexpression in breast cancer specimens from patients assigned to the good and poor prognosis groups.
Good prognosis
Poor prognosis
13 3 *P < 0.05 E-cadherin expression in good vs poor prognosis groups (Fisher exact test).
nent was individually analyzed using a sensitive method, which may allow measurements of expression levels as a continuous variable. In addition, three target genes, Ecadherin, Snail and Hakai, were concomitantly analyzed in the matched samples. Another study, carried out on a larger sample of matched tumor and metastasis specimens from ductal carcinomas, did not detect differences in E-cadherin protein staining intensity (9) . Taken together, these results and ours suggest that, in general, ductal carcinomas, represented by the primary tumor, its peritumoral tissue and its nodal metastases, maintain their E-cadherin expression throughout their development, including invasiveness and establishment in other tissues. On the other hand, a reduction of E-cadherin protein expression was reported in a small series of invasive ductal carcinomas as compared to ductal carcinomas in situ (12) . Differences between this analysis and ours were that samples were obtained from different patients and were not paired in the previous study. It was also reported that reduction or lack of E-cadherin protein expression in non-lobular breast cancer is preferentially found in basal-like carcinomas (13) . However, our samples were mainly represented by hormone receptorpositive tumors. Another consideration is that both studies analyzed E-cadherin protein expression, which is also regulated post-transcriptionally. In our study, Hakai mRNA was more expressed in 12/22 tumors compared to their matched peritumor samples, suggesting that E-cadherin degradation mediated by Hakai may be up-regulated at least in a few tumors. In addition, other mechanisms may be involved in E-cadherin down-regulation at the protein level (14, 15) that may occur through endocytosis (16, 17) , and these were not investigated here. A positive correlation between Snail and E-cadherin mRNA expression in invasive ductal carcinoma samples has been reported (18) , as also observed in the present study. In addition, although in vitro studies using cell lines have indicated that induced overexpression of Snail in mammary normal or transformed cell lines represses Ecadherin transcription, the same does not seem to occur in tumor samples (18) . Hence, observations in breast tumor samples underscore the role of other regulatory elements in addition to Snail in physiologic E-cadherin transcription regulation.
We also evaluated whether tumor expression of E-cadherin, Snail and Hakai mRNA could be related to regional metastasis since the presence of involved lymph nodes suggests that tumor spreading may have occurred through the lymphatics. However, we could not find any association. In agreement, no relation between lymph node involvement and E-cadherin immunohistochemical expression was detected by others in non-lobular carcinomas (8, 19) . Conversely, Snail overexpression in tumors from patients with node (18, 20) and distant metastases (21) has also been reported.
Circulating tumor cells were detected in three of the 13 patients tested, in agreement with results previously reported in clinical stage I-III breast cancer disease (22, 23) . Although we studied a small number of samples, we may speculate that there may be a trend towards a low E-cadherin expression in tumor samples from patients with circulating malignant cells that could facilitate tumor shedding through the vascular channels. Other investigators have not found a relation between blood vessel invasion and E-cadherin expression (24) . However, their sample also included lobular and other carcinoma samples and not just ductal carcinomas.
Complete absence of E-cadherin protein immunoexpression was observed in 10% of the tumors analyzed here, in agreement with data reported by others (8, 13, 25, 26) . In addition, positive E-cadherin expression was associated with a better prognosis, in agreement with a previous report (19) .
We detected Snail protein nuclear localization in just two of the 30 samples analyzed. Similarly, Rosivatz et al. (26) , studying a large series of adenocarcinomas of the upper gastrointestinal tract, observed nuclear Snail immunoreactivity in only 7.9% of them. We speculate that Snail may not be exerting its function as a transcriptional factor in ductal carcinomas. This is the first report to analyze the concomitant expression of CDH1, SNAI1 and Hakai mRNA in matched tumor and peritumoral samples from patients with invasive ductal carcinomas. Our data suggest that there is no clear pattern of expression of these target genes that may classify the tumor specimen and its adjacent normal tissue. Our study also indicates that tumor E-cadherin protein expression may be related to overall breast cancer survival.
